CR20160388A - Terapias de combinación con anticuerpos anti-cd38 - Google Patents
Terapias de combinación con anticuerpos anti-cd38Info
- Publication number
- CR20160388A CR20160388A CR20160388A CR20160388A CR20160388A CR 20160388 A CR20160388 A CR 20160388A CR 20160388 A CR20160388 A CR 20160388A CR 20160388 A CR20160388 A CR 20160388A CR 20160388 A CR20160388 A CR 20160388A
- Authority
- CR
- Costa Rica
- Prior art keywords
- antibodies
- combination therapies
- therapies
- combination
- relates
- Prior art date
Links
- 238000002648 combination therapy Methods 0.000 title abstract 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/65—Tetracyclines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4612—B-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4622—Antigen presenting cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001126—CD38 not IgG
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención se refiere a terapias de combinación con anticuerpos anti-CD38.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461946002P | 2014-02-28 | 2014-02-28 | |
US201462006386P | 2014-06-02 | 2014-06-02 | |
PCT/US2015/017420 WO2015130728A1 (en) | 2014-02-28 | 2015-02-25 | Combination therapies with anti-cd38 antibodies |
Publications (1)
Publication Number | Publication Date |
---|---|
CR20160388A true CR20160388A (es) | 2016-11-07 |
Family
ID=54006264
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR20160388A CR20160388A (es) | 2014-02-28 | 2015-02-25 | Terapias de combinación con anticuerpos anti-cd38 |
Country Status (34)
Country | Link |
---|---|
US (3) | US9603927B2 (es) |
EP (1) | EP3110843B1 (es) |
JP (1) | JP6670248B2 (es) |
KR (1) | KR20160126026A (es) |
CN (1) | CN106459184B (es) |
AU (1) | AU2015223205B2 (es) |
BR (1) | BR112016019866A2 (es) |
CA (1) | CA2940864C (es) |
CL (1) | CL2016002158A1 (es) |
CR (1) | CR20160388A (es) |
CY (1) | CY1122398T1 (es) |
DK (1) | DK3110843T3 (es) |
DO (1) | DOP2016000224A (es) |
EA (1) | EA201691747A1 (es) |
ES (1) | ES2756349T3 (es) |
GT (1) | GT201600172A (es) |
HR (1) | HRP20192058T1 (es) |
HU (1) | HUE046028T2 (es) |
IL (1) | IL247392B (es) |
LT (1) | LT3110843T (es) |
ME (1) | ME03583B (es) |
MX (1) | MX2016011186A (es) |
MY (1) | MY180621A (es) |
PE (1) | PE20161175A1 (es) |
PH (1) | PH12016501700A1 (es) |
PL (1) | PL3110843T3 (es) |
PT (1) | PT3110843T (es) |
RS (1) | RS59516B1 (es) |
SG (1) | SG11201607028XA (es) |
SI (1) | SI3110843T1 (es) |
SV (1) | SV2016005267A (es) |
UA (1) | UA120926C2 (es) |
WO (1) | WO2015130728A1 (es) |
ZA (2) | ZA201606682B (es) |
Families Citing this family (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11053316B2 (en) | 2013-01-14 | 2021-07-06 | Xencor, Inc. | Optimized antibody variable regions |
EP3620473A1 (en) | 2013-01-14 | 2020-03-11 | Xencor, Inc. | Novel heterodimeric proteins |
US10858417B2 (en) | 2013-03-15 | 2020-12-08 | Xencor, Inc. | Heterodimeric proteins |
US9603927B2 (en) * | 2014-02-28 | 2017-03-28 | Janssen Biotech, Inc. | Combination therapies with anti-CD38 antibodies |
US9732154B2 (en) | 2014-02-28 | 2017-08-15 | Janssen Biotech, Inc. | Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia |
UA119167C2 (uk) | 2014-03-28 | 2019-05-10 | Зенкор, Інк. | Біспецифічне антитіло, яке зв'язується з cd38 та cd3 |
MY192918A (en) | 2014-09-09 | 2022-09-15 | Janssen Biotech Inc | Combination therapies with anti-cd38 antibodies |
CN107406512A (zh) | 2014-11-26 | 2017-11-28 | Xencor公司 | 结合cd3和cd38的异二聚体抗体 |
EP3223845B1 (en) | 2014-11-26 | 2021-05-19 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and cd20 |
US10259887B2 (en) | 2014-11-26 | 2019-04-16 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and tumor antigens |
EP3227338A4 (en) | 2014-12-04 | 2018-05-16 | Janssen Biotech, Inc. | Anti-cd38 antibodies for treatment of acute myeloid leukemia |
MA41555A (fr) * | 2015-02-17 | 2017-12-26 | Millennium Pharm Inc | Polythérapie pour le traitement du cancer |
AU2016264725B2 (en) | 2015-05-20 | 2021-05-27 | Janssen Biotech, Inc. | Anti-CD38 antibodies for treatment of light chain amyloidosis and other CD38-positive hematological malignancies |
JP6816038B2 (ja) | 2015-06-22 | 2021-01-20 | ヤンセン バイオテツク,インコーポレーテツド | 抗cd38抗体及びサバイビン阻害剤による血液悪性疾患の併用療法 |
US20170044265A1 (en) | 2015-06-24 | 2017-02-16 | Janssen Biotech, Inc. | Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38 |
AU2016281717B2 (en) * | 2015-06-24 | 2022-07-28 | Janssen Biotech, Inc. | Immune modulation and treatment of solid tumors with antibodies that specifically bind CD38 |
US10781261B2 (en) | 2015-11-03 | 2020-09-22 | Janssen Biotech, Inc. | Subcutaneous formulations of anti-CD38 antibodies and their uses |
MA53356B1 (fr) | 2015-11-03 | 2022-05-31 | Janssen Biotech Inc | Formulations sous-cutanées d'anticorps anti-cd38 et leurs utilisations |
KR20180085800A (ko) | 2015-12-07 | 2018-07-27 | 젠코어 인코포레이티드 | Cd3 및 psma에 결합하는 이종이합체성 항체 |
MA45255A (fr) | 2016-06-14 | 2019-04-17 | Xencor Inc | Anticorps inhibiteurs de points de contrôle bispécifiques |
CN110167964B (zh) | 2016-11-02 | 2023-12-01 | 百时美施贵宝公司 | 组合用于治疗多发性骨髓瘤的针对bcma和cd3的双特异性抗体和免疫药物 |
EP3544612A4 (en) * | 2016-11-23 | 2020-05-13 | Acetylon Pharmaceuticals, Inc. | PHARMACEUTICAL COMBINATIONS COMPRISING A HISTONE DEACETYLASE INHIBITOR AND A CD38 INHIBITOR AND METHODS OF USING THE SAME |
US20200078362A1 (en) * | 2016-12-02 | 2020-03-12 | Epizyme, Inc. | Combination therapy for treating cancer |
WO2019035938A1 (en) | 2017-08-16 | 2019-02-21 | Elstar Therapeutics, Inc. | MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF |
CA3079242A1 (en) | 2017-10-31 | 2019-05-09 | Janssen Biotech, Inc. | Methods of treating high risk multiple myeloma |
WO2019111249A1 (en) | 2017-12-05 | 2019-06-13 | The Medical Research Infrastructure And Health Services Fund Of The Tel Aviv Medical Center | T-cells comprising anti-cd38 and anti-cd138 chimeric antigen receptors and uses thereof |
BR112020016929A8 (pt) | 2018-02-20 | 2022-06-28 | Agios Pharmaceuticals Inc | Métodos de uso para derivados de benzotriazol trissubstituídos |
KR101997519B1 (ko) * | 2018-03-16 | 2019-07-09 | 주식회사 지니틱스 | 디스플레이 패널로부터의 노이즈에 의한 영향 및 공정편차에 따른 에러를 제거하는 터치감지칩 |
EP3793606A4 (en) * | 2018-05-16 | 2022-08-31 | Janssen Biotech, Inc. | METHODS OF TREATMENT OF CANCER AND ENHANCEMENT OF THE EFFECTIVENESS OF T-CELL REFERRING THERAPEUTICS |
JP2022512722A (ja) | 2018-10-17 | 2022-02-07 | ヤンセン バイオテツク,インコーポレーテツド | 抗cd38抗体の皮下投与を提供する方法 |
SG11202104092UA (en) * | 2018-11-13 | 2021-05-28 | Janssen Biotech Inc | Control of trace metals during production of anti-cd38 antibodies |
US20220008513A1 (en) * | 2018-11-30 | 2022-01-13 | Fondazione Centro San Raffaele | Combined treatment of primary central nervous system lymphoma |
CN113710324A (zh) * | 2019-01-23 | 2021-11-26 | 千禧制药公司 | 抗cd38抗体 |
AU2020213103A1 (en) | 2019-01-23 | 2021-07-29 | Millennium Pharmaceuticals, Inc. | CD38-binding proteins comprising de-immunized Shiga toxin a subunit effectors |
US20220187309A1 (en) * | 2019-04-30 | 2022-06-16 | Sarah E. WHEELER | Compositions and methods for detection of disease-related antibody |
MX2022010549A (es) | 2020-02-26 | 2022-11-16 | Biograph 55 Inc | Moleculas de union compuestas que se dirigen a celulas b inmunodepresoras. |
US20210338766A1 (en) * | 2020-04-29 | 2021-11-04 | Onyx Pharmaceuticals, Inc. | Methods of treating multiple myeloma |
US11919956B2 (en) | 2020-05-14 | 2024-03-05 | Xencor, Inc. | Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3 |
IL300666A (en) | 2020-08-19 | 2023-04-01 | Xencor Inc | ANTI–CD28 COMPOSITIONS |
CA3190511A1 (en) * | 2020-08-27 | 2022-03-03 | John COCO | Use of a dhodh inhibitor compound in combination cancer therapy |
WO2022192403A1 (en) | 2021-03-09 | 2022-09-15 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and cldn6 |
EP4305065A1 (en) | 2021-03-10 | 2024-01-17 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and gpc3 |
US20230136301A1 (en) | 2021-11-03 | 2023-05-04 | Janssen Biotech, Inc. | Corticosteriod Reduction in Treatment with Anti-CD38 Antibody |
WO2023150677A2 (en) * | 2022-02-03 | 2023-08-10 | Igm Biosciences, Inc. | Anti-cd38 binding molecules and uses thereof |
Family Cites Families (98)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1989008114A1 (en) | 1988-02-25 | 1989-09-08 | The General Hospital Corporation | Rapid immunoselection cloning method |
CA2087272C (en) | 1990-07-13 | 2005-10-11 | Brian Seed | Cd53 cell surface antigen and use thereof |
AU6123894A (en) | 1993-01-29 | 1994-08-15 | Board Of Trustees Of The Leland Stanford Junior University | Modulation of physiological responses of lymphocytes by cd38 or antibodies thereto |
GB9424449D0 (en) | 1994-12-02 | 1995-01-18 | Wellcome Found | Antibodies |
WO1998016245A1 (fr) | 1996-10-15 | 1998-04-23 | Shionogi & Co., Ltd. | Procede de determination d'un auto-anticorps |
US6083477A (en) | 1996-10-17 | 2000-07-04 | Immunomedics, Inc. | Non-antigenic toxin-conjugate and fusion protein of internalizing receptor system |
WO2000006194A2 (en) | 1997-02-05 | 2000-02-10 | Biotransplant, Inc. | Depletion of cells responsible for antibody-mediated graft rejection |
DE69831224T2 (de) | 1997-05-02 | 2006-03-23 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Immuntoxine, die ein onc protein enthalten, gegen bösartige zellen |
AU770718B2 (en) | 1998-06-05 | 2004-02-26 | Mayo Foundation For Medical Education And Research | Use of genetically engineered antibodies to CD38 to treat multiple myeloma |
US7223397B1 (en) | 1999-01-07 | 2007-05-29 | Research Development Foundation | Potentiation of anti-CD38-Immunotoxin cytotoxicity |
US7183387B1 (en) | 1999-01-15 | 2007-02-27 | Genentech, Inc. | Polypeptide variants with altered effector function |
US6737056B1 (en) * | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
US7829693B2 (en) | 1999-11-24 | 2010-11-09 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of a target gene |
FR2807767B1 (fr) | 2000-04-12 | 2005-01-14 | Lab Francais Du Fractionnement | Anticorps monoclonaux anti-d |
AU6541801A (en) * | 2000-06-22 | 2002-01-02 | Idec Pharma Corp | Bispecific fusion protein and method of use for enhancing effector cell killing of target cells |
EP1174440A1 (en) | 2000-07-19 | 2002-01-23 | U-BISys B.V. | A selectively-expressed epitope on the human CD38 molecule detected by a phage display library-derived human scFv antibody fragment |
US20070042436A1 (en) | 2000-10-17 | 2007-02-22 | Lund Frances E | CD38 modulated chemotaxis |
CA2424643A1 (en) | 2000-10-17 | 2002-04-25 | Trudeau Institute, Inc. | Cd38 modulated chemotaxis |
US20040166490A1 (en) | 2002-12-17 | 2004-08-26 | Morris David W. | Novel therapeutic targets in cancer |
ES2295639T3 (es) | 2002-06-13 | 2008-04-16 | Crucell Holland B.V. | Agonistas del receptor ox40=(=cd134) y uso terapeutico descripcion. |
SG177008A1 (en) | 2003-03-05 | 2012-01-30 | Halozyme Inc | Soluble hyaluronidase glycoprotein (shasegp), process for preparing the same, uses and pharmaceutical compositions comprising thereof |
RS20150135A1 (en) | 2003-05-30 | 2015-08-31 | Genentech Inc. | TREATMENT WITH ANTI-VEGF ANTIBODIES |
US7902338B2 (en) * | 2003-07-31 | 2011-03-08 | Immunomedics, Inc. | Anti-CD19 antibodies |
EP1689435A4 (en) | 2003-10-22 | 2007-10-03 | Univ Rochester | ANTI-THYMOCYTE ANTISERUM AND ITS USE FOR TRIGGERING B-CELL APOPTOSIS |
US20070218060A1 (en) | 2003-11-04 | 2007-09-20 | Chiron Corporation | Use of Antagonist Anti-Cd40 Monoclonal Antibodies for Treatment of Multiple Myeloma |
WO2005063819A2 (en) | 2003-12-23 | 2005-07-14 | Crucell Holland B.V. | Human binding molecule against cd1a |
EP1720907B1 (en) | 2004-02-06 | 2015-04-08 | MorphoSys AG | Anti-cd38 human antibodies and uses therefor |
CA2555185C (en) | 2004-02-06 | 2020-03-24 | Morphosys Ag | Anti-cd38 human antibodies and uses therefor |
WO2006125640A2 (en) | 2005-05-24 | 2006-11-30 | Morphosys Ag | Generation and profiling of fully human hucal gold®-derived therapeutic antibodies specific for human cd38 |
SI2567976T1 (sl) | 2005-03-23 | 2017-11-30 | Genmab A/S | Protitelesa usmerjena proti cd38 za zdravljenje multiplega mieloma |
AU2006301446B2 (en) | 2005-10-12 | 2012-06-07 | Morphosys Ag | Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human CD38 |
EP1968636A4 (en) * | 2005-12-09 | 2010-06-02 | Seattle Genetics Inc | METHOD OF USE OF CD40 BONDING AGENTS |
JP2009545601A (ja) | 2006-08-02 | 2009-12-24 | サネシス ファーマシューティカルズ, インコーポレイテッド | (+)−1,4−ジヒドロ−7−[(3s,4s)−3−メトキシ−4−(メチルアミノ)−1−ピロリジニル]−4−オキソ−1−(2−チアゾリル)−1,8−ナフチリジン−3−カルボン酸の組合せ使用 |
WO2008073160A2 (en) | 2006-08-17 | 2008-06-19 | The Trustees Of Columbia University In The City Of New York | Methods for converting or inducing protective immunity |
SI2081595T1 (sl) * | 2006-09-26 | 2019-10-30 | Genmab As | Anti-cd38 plus kortikosteroidi plus ne-kortikosteroidni kemoterapevtik za zdravljenje tumorjev |
EP1914242A1 (en) | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
US7618992B2 (en) | 2006-12-29 | 2009-11-17 | Astellas Pharma Inc. | Method of treating cancer by co-administration of anticancer agents |
CN101970001A (zh) | 2007-06-01 | 2011-02-09 | 比奥根艾迪克Ma公司 | Cripto结合分子 |
US20090076249A1 (en) | 2007-09-19 | 2009-03-19 | Michel De Weers | Antibodies against CD38 for treatment of multiple myeloma |
RU2491095C2 (ru) * | 2007-11-09 | 2013-08-27 | Новартис Аг | Применения анти-cd40-антител |
WO2009062504A1 (en) | 2007-11-13 | 2009-05-22 | Tnm Farmguard Aps | Secure communication between a client and devices on different private local networks using the same subnet addresses |
WO2009074807A2 (en) | 2007-12-12 | 2009-06-18 | Imperial Innovations Limited | Methods |
CA2717803A1 (en) | 2008-03-03 | 2009-09-11 | Dyax Corp. | Metalloproteinase 9 and metalloproteinase 2 binding proteins |
PT2268310T (pt) * | 2008-03-25 | 2016-08-23 | Roche Glycart Ag | Uso de um anticorpo anti-cd20 do tipo ii com citotoxicidade celular acrescida dependente de anticorpo (adcc) em combinação com ciclofosfamida, vincristina e doxorubicina para tratar linfomas não-hodgkin |
EP3192525A1 (en) | 2008-04-14 | 2017-07-19 | Halozyme, Inc. | Modified hyaluronidases for use in treating hyaluronan-associated diseases and conditions |
LT2982696T (lt) | 2008-11-07 | 2019-06-10 | Amgen Research (Munich) Gmbh | Ūmios limfoblastinės leukemijos gydymas |
EP2191840A1 (en) | 2008-11-28 | 2010-06-02 | Sanofi-Aventis | Antitumor combinations containing antibodies recognizing specifically CD38 and melphalan |
EP2191843A1 (en) | 2008-11-28 | 2010-06-02 | Sanofi-Aventis | Antitumor combinations containing antibodies recognizing specifically CD38 and cyclophosphamide |
EP2191842A1 (en) | 2008-11-28 | 2010-06-02 | Sanofi-Aventis | Antitumor combinations containing antibodies recognizing specifically CD38 and cytarabine |
EP2191841A1 (en) * | 2008-11-28 | 2010-06-02 | Sanofi-Aventis | Antitumor combinations containing antibodies recognizing specifically CD38 and vincristine |
PT2429524T (pt) | 2009-05-14 | 2020-03-02 | Ambit Biosciences Corp | Formulação de ac220 seca por atomização |
AR078161A1 (es) | 2009-09-11 | 2011-10-19 | Hoffmann La Roche | Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento. |
MX2012003282A (es) | 2009-09-17 | 2012-04-30 | Baxter Healthcare Sa | Co-formulacion estable de hialuronidasa e inmunoglobulina, y metodos de su uso. |
CA2776385C (en) | 2009-10-07 | 2019-04-09 | Macrogenics, Inc. | Fc region-containing polypeptides that exhibit improved effector function due to alterations of the extent of fucosylation, and methods for their use |
EP2327725A1 (en) | 2009-11-26 | 2011-06-01 | InflaRx GmbH | Anti-C5a binding moieties with high blocking activity |
GB201003701D0 (en) | 2010-03-05 | 2010-04-21 | Cilian Ag | System for the expression of a protein |
WO2011121588A1 (en) | 2010-03-29 | 2011-10-06 | Ben Gurion University Of The Negev Research And Development Authority | Method and system for detecting and monitoring hematological cancer |
LT2580243T (lt) | 2010-06-09 | 2020-01-27 | Genmab A/S | Antikūnai prieš žmogaus cd38 |
KR101912957B1 (ko) | 2010-09-27 | 2018-10-29 | 모르포시스 아게 | 다발성 골수종 및 nhl 치료를 위한 항-cd38 항체 및 레날리도마이드 또는 보르테조밉 |
US9358233B2 (en) | 2010-11-29 | 2016-06-07 | Boehringer Ingelheim International Gmbh | Method for treating acute myeloid leukemia |
UA112170C2 (uk) | 2010-12-10 | 2016-08-10 | Санофі | Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб |
CL2013001944A1 (es) | 2010-12-30 | 2014-09-12 | Takeda Pharmaceutical | Anticuerpo aislado que se une especificamente a cd38 humana y cd38 de cinomolgo; acido nucleico que lo codifica; celula huesped; metodo de produccion; y su uso para tratar una enfermedad autoinmune. |
JOP20210044A1 (ar) | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | الأجسام المضادة لـ cd38 |
WO2012129344A1 (en) | 2011-03-23 | 2012-09-27 | Amgen Inc. | Fused tricyclic dual inhibitors of cdk 4/6 and flt3 |
EP2561868A1 (en) | 2011-08-24 | 2013-02-27 | Anton Bernhard Van Oosten | Pharmaceutical compositions comprising hydroxychloroquine (HCQ), Curcumin, Piperine/BioPerine and uses thereof in the medical field |
EP3559049A4 (en) | 2011-10-28 | 2019-12-04 | Teva Pharmaceuticals Australia Pty Ltd | POLYPEPTIDE CONSTRUCTS AND APPLICATIONS THEREOF |
SI2833905T1 (en) | 2012-04-04 | 2018-08-31 | Halozyme, Inc. | Combination therapy with hyaluronidase and tumane-directed taxane |
US9212224B2 (en) | 2012-05-15 | 2015-12-15 | Bristol-Myers Squibb Company | Antibodies that bind PD-L1 and uses thereof |
US9682143B2 (en) | 2012-08-14 | 2017-06-20 | Ibc Pharmaceuticals, Inc. | Combination therapy for inducing immune response to disease |
EP2914302B1 (en) | 2012-11-05 | 2017-01-04 | MorphoSys AG | Radiolabelled antibody and uses thereof |
UA118255C2 (uk) | 2012-12-07 | 2018-12-26 | Санофі | Композиція, яка містить антитіло до cd38 і леналідомід |
WO2014142220A1 (ja) | 2013-03-13 | 2014-09-18 | アステラス製薬株式会社 | 抗腫瘍剤 |
US20140271644A1 (en) | 2013-03-15 | 2014-09-18 | Memorial Sloan-Kettering Cancer Center | Combination/adjuvant therapy for wt-1-positive disease |
AU2013388126B2 (en) * | 2013-04-29 | 2019-03-07 | Teva Pharmaceuticals Australia Pty Ltd. | Anti-CD38 antibodies and fusions to attenuated interferon alpha-2b |
US20140356318A1 (en) | 2013-05-28 | 2014-12-04 | Israel Barken | Adoptive cell therapy with specific regulatory lymphocytes |
US20160235842A1 (en) | 2013-07-15 | 2016-08-18 | The Board Of Trustees Of The Leland Stanford Junior University | Medical uses of cd38 agonists |
TN2016000142A1 (en) | 2013-10-31 | 2017-10-06 | Sanofi Sa | Specific anti-cd38 antibodies for treating human cancers. |
EP3066125A2 (en) | 2013-11-06 | 2016-09-14 | Boehringer Ingelheim International GmbH | Pharmaceutical combinations comprising cd33 antibodies and de-methylating agents |
US9732154B2 (en) | 2014-02-28 | 2017-08-15 | Janssen Biotech, Inc. | Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia |
US9603927B2 (en) | 2014-02-28 | 2017-03-28 | Janssen Biotech, Inc. | Combination therapies with anti-CD38 antibodies |
US10106620B2 (en) | 2014-06-16 | 2018-10-23 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Blocking CD38 using anti-CD38 F(ab′)2 to protect NK cells |
WO2015195555A1 (en) | 2014-06-16 | 2015-12-23 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Blocking cd38 using anti-cd38 antibody conjugated to protein g to protect nk cells |
US9499514B2 (en) | 2014-07-11 | 2016-11-22 | Celgene Corporation | Antiproliferative compounds and methods of use thereof |
MY192918A (en) | 2014-09-09 | 2022-09-15 | Janssen Biotech Inc | Combination therapies with anti-cd38 antibodies |
EP3227338A4 (en) | 2014-12-04 | 2018-05-16 | Janssen Biotech, Inc. | Anti-cd38 antibodies for treatment of acute myeloid leukemia |
MA41555A (fr) | 2015-02-17 | 2017-12-26 | Millennium Pharm Inc | Polythérapie pour le traitement du cancer |
AU2016264725B2 (en) | 2015-05-20 | 2021-05-27 | Janssen Biotech, Inc. | Anti-CD38 antibodies for treatment of light chain amyloidosis and other CD38-positive hematological malignancies |
JP6816038B2 (ja) | 2015-06-22 | 2021-01-20 | ヤンセン バイオテツク,インコーポレーテツド | 抗cd38抗体及びサバイビン阻害剤による血液悪性疾患の併用療法 |
AU2016281717B2 (en) | 2015-06-24 | 2022-07-28 | Janssen Biotech, Inc. | Immune modulation and treatment of solid tumors with antibodies that specifically bind CD38 |
US20170044265A1 (en) | 2015-06-24 | 2017-02-16 | Janssen Biotech, Inc. | Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38 |
US20170121417A1 (en) | 2015-11-03 | 2017-05-04 | Janssen Biotech, Inc. | Subcutaneous Formulations of Anti-CD38 Antibodies and Their Uses |
MA53356B1 (fr) | 2015-11-03 | 2022-05-31 | Janssen Biotech Inc | Formulations sous-cutanées d'anticorps anti-cd38 et leurs utilisations |
US10781261B2 (en) | 2015-11-03 | 2020-09-22 | Janssen Biotech, Inc. | Subcutaneous formulations of anti-CD38 antibodies and their uses |
EP3474895A1 (en) | 2016-06-28 | 2019-05-01 | UMC Utrecht Holding B.V. | TREATMENT OF IgE-MEDIATED DISEASES WITH ANTIBODIES THAT SPECIFICALLY BIND CD38 |
US20180117150A1 (en) | 2016-11-01 | 2018-05-03 | Janssen Biotech, Inc. | Combination Therapies for CD38-Positive Hematological Malignances with ANTI-CD38 Antibodies and Cyclophosphamide |
CA3079242A1 (en) | 2017-10-31 | 2019-05-09 | Janssen Biotech, Inc. | Methods of treating high risk multiple myeloma |
BR112020019710A2 (pt) | 2018-03-28 | 2021-01-26 | Takeda Pharmaceutical Company Limited | métodos para tratar uma doença em um sujeito e para tratar um câncer hematológico em um sujeito, e, forma farmacêutica unitária. |
JP2022512722A (ja) | 2018-10-17 | 2022-02-07 | ヤンセン バイオテツク,インコーポレーテツド | 抗cd38抗体の皮下投与を提供する方法 |
-
2015
- 2015-02-24 US US14/629,941 patent/US9603927B2/en active Active
- 2015-02-25 MY MYPI2016703119A patent/MY180621A/en unknown
- 2015-02-25 CR CR20160388A patent/CR20160388A/es unknown
- 2015-02-25 PL PL15755187T patent/PL3110843T3/pl unknown
- 2015-02-25 SI SI201530903T patent/SI3110843T1/sl unknown
- 2015-02-25 MX MX2016011186A patent/MX2016011186A/es unknown
- 2015-02-25 SG SG11201607028XA patent/SG11201607028XA/en unknown
- 2015-02-25 AU AU2015223205A patent/AU2015223205B2/en active Active
- 2015-02-25 WO PCT/US2015/017420 patent/WO2015130728A1/en active Application Filing
- 2015-02-25 PT PT157551870T patent/PT3110843T/pt unknown
- 2015-02-25 HU HUE15755187A patent/HUE046028T2/hu unknown
- 2015-02-25 DK DK15755187T patent/DK3110843T3/da active
- 2015-02-25 EP EP15755187.0A patent/EP3110843B1/en active Active
- 2015-02-25 EA EA201691747A patent/EA201691747A1/ru unknown
- 2015-02-25 ES ES15755187T patent/ES2756349T3/es active Active
- 2015-02-25 RS RS20191455A patent/RS59516B1/sr unknown
- 2015-02-25 CN CN201580022840.0A patent/CN106459184B/zh active Active
- 2015-02-25 UA UAA201609908A patent/UA120926C2/uk unknown
- 2015-02-25 BR BR112016019866A patent/BR112016019866A2/pt active Search and Examination
- 2015-02-25 PE PE2016001547A patent/PE20161175A1/es unknown
- 2015-02-25 LT LT15755187T patent/LT3110843T/lt unknown
- 2015-02-25 CA CA2940864A patent/CA2940864C/en active Active
- 2015-02-25 JP JP2016554350A patent/JP6670248B2/ja active Active
- 2015-02-25 KR KR1020167026215A patent/KR20160126026A/ko not_active Application Discontinuation
- 2015-02-25 ME MEP-2019-319A patent/ME03583B/me unknown
-
2016
- 2016-08-21 IL IL247392A patent/IL247392B/en active IP Right Grant
- 2016-08-25 CL CL2016002158A patent/CL2016002158A1/es unknown
- 2016-08-26 PH PH12016501700A patent/PH12016501700A1/en unknown
- 2016-08-26 GT GT201600172A patent/GT201600172A/es unknown
- 2016-08-26 DO DO2016000224A patent/DOP2016000224A/es unknown
- 2016-08-29 SV SV2016005267A patent/SV2016005267A/es unknown
- 2016-09-27 ZA ZA2016/06682A patent/ZA201606682B/en unknown
-
2017
- 2017-02-28 US US15/445,225 patent/US10800851B2/en active Active
- 2017-12-15 ZA ZA2017/08541A patent/ZA201708541B/en unknown
-
2019
- 2019-11-13 HR HRP20192058TT patent/HRP20192058T1/hr unknown
- 2019-12-09 CY CY20191101293T patent/CY1122398T1/el unknown
-
2020
- 2020-09-08 US US17/015,017 patent/US20210061920A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1122398T1 (el) | Συνδυαστικες θεραπειες με αντισωματα anti-cd38 | |
CL2017000559A1 (es) | Terapias de combinación con anticuerpos anti-cd38. | |
DOP2018000181A (es) | Terapias de combinación para enfermedades malignas hematológicas con anticuerpos anti-cd38 e inhibidores de survivina | |
TR201905829T4 (tr) | Buzdolabı. | |
CO2017003118A2 (es) | Arnés de seguridad con un ensamblaje de distribución de peso”. | |
BR112016019871A2 (pt) | anticorpos anti-cd38 para o tratamento de leucemia linfoblástica aguda | |
SG10201811017QA (en) | Novel antibody frameworks | |
TN2014000468A1 (fr) | اختراع الة للف شباك مراكب الصيد البحري و تسهيل تحويلها من المركب الى رصيف الميناء ثم ارجاعها للمركب بعد القيام بعملية ترقيعها | |
TN2014000355A1 (fr) | طريقة مبتكرة لتوفير الاضاءة العامة و المنزلية | |
GT201400038S (es) | Diseño de motocicleta | |
GT201400037S (es) | Diseño de motocicleta | |
TH1601005811B (th) | โครงสร้างส่วนประดับด้านหน้าของรถจักรยานยนต์ | |
GT201400051S (es) | Escúter o motoneta | |
TN2014000377A1 (fr) | طائرة كهربائية كاتمة للصوت | |
TH1401006497B (th) | ยานพาหนะประเภทอานนั่ง | |
AU358556S (en) | Strap fastener | |
GT201400039S (es) | Diseño de bici-motocicleta |